The emerging medical tech companies are fond of referring to their innovation as a “platform technologies” with a wide range of potential applicationscapable of solving numerous unmet clinical needs. Examples of platform technologies may include:
• Low-intensity, alternating electric fieldsable to manipulate and control cellular division,
• Miniaturized implantable pulse generators able to stimulate nerves,
• 3D bioprinting able to replicate cell patterns,
• Micro and nanofluidics able to channel fluid flow able to integrate and automate multiple assays,
• Robotic surgical tools able to perform anastomosis of tissues in critical surgeries in confined spaces
Platform technology can provide an opportunity to reduce development time for individual technologies and may offer economies of scale in research and development, prototypegeneration, manufacturing costs, verification and validation, and more.
However, emerging companiessecure investment capital for development and commercialization of a single initial compelling technology able to solve a confirmed unmet clinical need. This is because investors desire returns in investment multiples that are most often achieved with laser focused development efforts for a primary indication. The addressable market should be sufficiently large such that a reasonable market share would move the revenue line of a potential acquirer. Most investors seek a minimum of a $100 million dollar estimated market, and prefer a market several foldthat size.
This reality requires creative inventors identify and allocate human and financial resources towards those indications for use with the highest probability for successful commercialization. The question is, how do emerging entrepreneurs objectively determine which indication has manageable risk, a window of opportunity among existing and emerging competitors, and is anticipated to enjoy robust adoption from the target market. The answer is to secure a medical device market analysis consultant and perform a Commercialization Strategy and Competitive Analysis.
The Commercialization Strategy serves to outline framework to achieve the highest ROI confirming market size, projected adoption, competitive landscape and risk analysis for defensible revenue projects. Both primary and robust secondary data will construct the blueprint for a strong foundation.
The Competitive Analysis provides a complete evaluation of the current competitive landscape including the potential market space, product positioning and specific analysis of those features that deliver the highest value to the target market.
A medical device consultant with the requisite experience can expedite the capture of early investments preparing the documents that will engender confidence and commitment of investors. The analysis will also ensure that vital resources will be accurately allocated.
• Low-intensity, alternating electric fieldsable to manipulate and control cellular division,
• Miniaturized implantable pulse generators able to stimulate nerves,
• 3D bioprinting able to replicate cell patterns,
• Micro and nanofluidics able to channel fluid flow able to integrate and automate multiple assays,
• Robotic surgical tools able to perform anastomosis of tissues in critical surgeries in confined spaces
Platform technology can provide an opportunity to reduce development time for individual technologies and may offer economies of scale in research and development, prototypegeneration, manufacturing costs, verification and validation, and more.
 |
| Platform Technologies |
However, emerging companiessecure investment capital for development and commercialization of a single initial compelling technology able to solve a confirmed unmet clinical need. This is because investors desire returns in investment multiples that are most often achieved with laser focused development efforts for a primary indication. The addressable market should be sufficiently large such that a reasonable market share would move the revenue line of a potential acquirer. Most investors seek a minimum of a $100 million dollar estimated market, and prefer a market several foldthat size.
This reality requires creative inventors identify and allocate human and financial resources towards those indications for use with the highest probability for successful commercialization. The question is, how do emerging entrepreneurs objectively determine which indication has manageable risk, a window of opportunity among existing and emerging competitors, and is anticipated to enjoy robust adoption from the target market. The answer is to secure a medical device market analysis consultant and perform a Commercialization Strategy and Competitive Analysis.
The Commercialization Strategy serves to outline framework to achieve the highest ROI confirming market size, projected adoption, competitive landscape and risk analysis for defensible revenue projects. Both primary and robust secondary data will construct the blueprint for a strong foundation.
The Competitive Analysis provides a complete evaluation of the current competitive landscape including the potential market space, product positioning and specific analysis of those features that deliver the highest value to the target market.
A medical device consultant with the requisite experience can expedite the capture of early investments preparing the documents that will engender confidence and commitment of investors. The analysis will also ensure that vital resources will be accurately allocated.
